Surgical Innovations Group (LSE:SUN) Stock Based Compensation: £0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Surgical Innovations Group Stock Based Compensation?

Surgical Innovations Group LSE:SUN Stock Based Compensation is £0.00 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Surgical Innovations Group's Stock Based Compensation for the six months ended in Dec. 2025 was £0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was £0.00 Mil.

Surgical Innovations Group Stock Based Compensation Related Terms

Surgical Innovations Group Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Surgical Innovations Group's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Surgical Innovations Group Stock Based Compensation Chart

Surgical Innovations Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.04 0.03 0.00 0.00

Surgical Innovations Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.00 0.00 0.00 0.00

Surgical Innovations Group Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

What does a Stock Based Compensation of £0.00 Mil mean?
Surgical Innovations Group (LSE:SUN) has a Stock Based Compensation of £0.00 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Surgical Innovations Group and its competitors.
Is Surgical Innovations Group's Stock Based Compensation too high?
Surgical Innovations Group's current Stock Based Compensation is £0.00 Mil.
How does Surgical Innovations Group's Stock Based Compensation compare to ABT and SYK?
Surgical Innovations Group's Stock Based Compensation of £0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Surgical Innovations Group and its competitors. Surgical Innovations Group's current Stock Based Compensation is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Innovations Group stock overvalued right now?
Surgical Innovations Group (LSE:SUN) has a current Stock Based Compensation of £0.00 Mil. The current Stock Based Compensation is £0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Surgical Innovations Group (LSE:SUN), the current Stock Based Compensation is £0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Surgical Innovations Group Business Description

Address Clayton Wood House, 6 Clayton Wood Bank, Leeds, GBR, LS16 6QZ
Surgical Innovations Group PLC is involved in the design, development, manufacture, and sale of devices for use in minimally invasive surgery (SI Brand), along with its label products through original equipment manufacturer (OEM) relationships, including precision engineering markets (PE). The Company's operating segments are SI Brand, OEM, and Distribution. The majority of its revenue is generated from the SI Brand segment, which is involved in the research, development, manufacture, and distribution of SI-branded minimally invasive devices. Geographically, the group derives a majority of its revenue from the United Kingdom, followed by Europe, the United States, the Asia-Pacific region, and the Rest of the world.